<DOC>
	<DOCNO>NCT00081510</DOCNO>
	<brief_summary>Primary Objective ( ) : - To compare activity ( progression-free survival [ PFS ] ) anastrozole combination lonafarnib anastrozole combination placebo subject hormone-sensitive ADVANCED breast cancer . Secondary Objective ( ) : - To determine effect anastrozole combination lonafarnib objective response , duration response , overall survival , safety subject advance breast cancer . To assess exposure pharmacokinetics lonafarnib anastrozole subject population .</brief_summary>
	<brief_title>Anastrozole Plus Lonafarnib ( SCH 66336 ) Plus Placebo Treatment Advanced Breast Cancer ( P03480 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal woman histologicallyconfirmed breast cancer follow characteristic : estrogen and/or progesterone receptor positive , locally advanced disease distant metastatic disease , stage 4 Subjects eligible singleagent treatment aromatase inhibitor current disease . Subjects take biophosphonates allow begin bisphosphonate therapy AT LEAST two week prior randomization . Measurable disease ( mass clearly define margin radiological image least one diameter &gt; =20 mm [ &gt; =10 mm spiral CT ] ) evaluable disease ( mass margin clearly define radiological image diameter &gt; = 20 mm ) . Subjects bone disease permit disease evaluable . ECOG Performance Status 0 1 . Sufficient bone marrow reserve . Adequate hepatic renal function : laboratory value within protocol requirement . Subjects receive one regimen cytotoxic chemotherapy advanced disease . Subjects CLINICALLY APPARENT brain metastasis extensive visceral disease , include extensive hepatic involvement pulmonary lymphangitic spread tumor . Subjects prior treatment FTIs . Subjects know suspected hypersensitivity excipients lonafarnib formulation ( Providone , Poloxamer 188 , croscarmellose sodium , silicon dioxide , magnesium stearate ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>